CS
IRON icon

Candriam SCA’s Disc Medicine IRON Stock Holding History

Candriam SCA’s Portfolio IRON Stock Details IRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-80,000
Closed -$4.98M – 705
2024
Q1 		$4.98M Hold
80,000
– – 0.03% 342
2023
Q4 		$4.62M Buy
+80,000
New +$4.1M 0.03% 341

Other funds holding IRON

PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Candriam SCA's IRON Position: Q2 2024 in Review

Candriam SCA sold out of Disc Medicine (IRON) in Q2 2024, closing a stake of 80,000 shares — an estimated $4.98M sold.

Candriam SCA first reported a position in IRON in Q4 2023 and held it in 2 quarters. The position peaked at $4.98M in Q1 2024. 121 funds tracked by Wall St. Rank hold IRON as of Q2 2024.

  • Candriam SCA reported no remaining Disc Medicine position as of Q2 2024 after selling out during the quarter.
  • Candriam SCA sold 80,000 Disc Medicine shares in Q2 2024, an estimated $4.98M.
  • Candriam SCA first reported a position in Disc Medicine in Q4 2023 and held it in 2 quarters.
  • Candriam SCA's Disc Medicine position peaked at $4.98M in Q1 2024.
  • 121 funds tracked by Wall St. Rank held Disc Medicine as of Q2 2024.

Based on Candriam SCA's 13F filing for Q2 2024, filed 5 Aug 2024.